CME Group Sues CFTC Over Kalshi Perpetual Futures Approval
CME Group sued the Commodity Futures Trading Commission (CFTC) on Thursday, alleging the agency erred in its approval of Kalshi’s first U.S. perpetual futures product. The lawsuit challenges the regulatory process the agency used to authorize the new financial instrument.
Why did CME Group sue the CFTC?
CME Group alleges the CFTC was wrong in how it handled the approval of Kalshi’s perpetual futures product. The legal action focuses on the agency’s decision-making process regarding this specific U.S. offering.
What are the implications of this lawsuit?
This dispute suggests a conflict over the standards the CFTC applies when approving new products. The outcome could impact how the agency evaluates future applications from other market participants.

What may happen next in the legal proceedings?
The court may review the CFTC’s approval process to determine if the agency acted incorrectly. A possible next step could be a judicial ruling that either upholds the approval or requires the CFTC to reconsider its decision regarding Kalshi.
Frequently Asked Questions
Who filed the lawsuit against the CFTC?
CME Group filed the lawsuit on Thursday.
What is the core of the legal dispute?
CME Group alleges the CFTC was wrong in how it approved Kalshi’s first U.S. perpetual futures product.
Which product is involved in the lawsuit?
The lawsuit involves the first U.S. perpetual futures product approved for Kalshi.
How do you think regulatory disputes between major exchanges and government agencies affect market competition?